Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
30
07
2019
accepted:
28
11
2019
revised:
12
11
2019
pubmed:
13
12
2019
medline:
9
3
2021
entrez:
13
12
2019
Statut:
ppublish
Résumé
To investigate the effectiveness and safety of SoracteLite™-transperineal percutaneous laser ablation (TPLA) in the treatment of patients with symptomatic benign prostatic hyperplasia (BPH) at 6 and 12 months follow-up. Patients with urinary symptoms secondary to BPH underwent TPLA under local anesthesia in four centers. Under US guidance, up to four 21G applicators were inserted in the prostatic tissue. Each treatment was performed with diode laser operating at 1064 nm changing the illumination time according to prostate size. The primary end-points of this study were change in IPSS, PVR, Qmax, QoL, and prostatic volume at 6 an 12 months from SoracteLite Analysis was performed on data 160 patients (mean age 69.8 ± 9.6 years) with at least 6 months follow and of 83 patients (mean age 67.9 ± 8.7 years) with at least 12 months follow-up. At 6 months, IPSS improved from 22.5 ± 5.1 to 7.7 ± 3.3 (P < 0.001), PVR from 89.5 ± 84.6 to 27.2 ± 44.5 ml (P < 0.001), Qmax from 8.0 ± 3.8 to 14.3 ± 3.9 ml/s (P < 0.001), QoL from 4.5 ± 1.1 to 1.8 ± 1.0 (P < 0.001), volume from 75.0 ± 32.4 to 60.3 ± 24.5 ml (P < 0.001). At 12 months, IPSS improved from 22.5 ± 4.5 to 7.0 ± 2.9 (P < 0.001), PVR from 71.7 ± 93.9 to 17.8 ± 51.0 ml (P < 0.001), Qmax from 8.6 ± 5.2 to 15.0 ± 4.0 ml/s (P < 0.001), QoL from 4.2 ± 0.6 to 1.6 ± 0.9 (P < 0.001), volume from 87.9 ± 31.6 to 58.8 ± 22.9 ml (P < 0.001). 7/160 (4.3%) grade I and 1/160 (0.6%) grade III complication occurred. SoracteLite™ TPLA allows significant improvement of IPSS, Qol, Qmax, PVR, and reduction of prostatic volume at 6 and 12 months.
Identifiants
pubmed: 31827239
doi: 10.1038/s41391-019-0196-4
pii: 10.1038/s41391-019-0196-4
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
356-363Références
Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep. 2010;5:212–8.
pubmed: 21475707
pmcid: 3061630
doi: 10.1007/s11884-010-0067-2
Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA, et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology. 2009;73:562–6.
pubmed: 19167031
doi: 10.1016/j.urology.2008.05.034
Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol. 2008;10:14–25.
pubmed: 18470272
pmcid: 2312341
Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67:1066–96.
pubmed: 24972732
doi: 10.1016/j.eururo.2014.06.017
Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)–incidence, management, and prevention. Eur Urol. 2006;50:969–79. discussion 980
pubmed: 16469429
doi: 10.1016/j.eururo.2005.12.042
Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol. 2006;6:14.
pubmed: 16790044
pmcid: 1538609
doi: 10.1186/1471-2490-6-14
Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology. 2012;79:1111–6.
pubmed: 22546389
pmcid: 3415208
doi: 10.1016/j.urology.2011.11.084
Perera M, Roberts MJ, Doi SA, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2015;67:704–13.
pubmed: 25466940
doi: 10.1016/j.eururo.2014.10.031
Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol. 2015;22:7772–82.
pubmed: 26068624
Yildiz G, Bahouth Z, Halachmi S, Meyer G, Nativ O, Moskovitz B. Allium TPS–a new prostatic stent for the treatment of patients with benign prostatic obstruction: the first report. J Endourol. 2016;30:319–22.
pubmed: 26472166
doi: 10.1089/end.2015.0593
El-Husseiny T, Buchholz N. Transurethral ethanol ablation of the prostate for symptomatic benign prostatic hyperplasia: long-term follow-up. J Endourol. 2011;25:477–80.
pubmed: 21355774
doi: 10.1089/end.2010.0201
Shore N, Cowan B. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis. 2011;2:377–83.
pubmed: 23251763
pmcid: 3513892
doi: 10.1177/2040622311423128
Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol. 2013;189:1421–6.
pubmed: 23142202
doi: 10.1016/j.juro.2012.11.003
Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013;63:496–503.
pubmed: 23098762
doi: 10.1016/j.eururo.2012.10.005
McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled rezum system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2018;111:1–9.
pubmed: 29122620
doi: 10.1016/j.urology.2017.10.023
Schreuder SM, Scholtens AE, Reekers JA, Bipat S. The role of prostatic arterial embolization in patients with benign prostatic hyperplasia: a systematic review. Cardiovasc Interventional Radiol. 2014;37:1198–1219.
doi: 10.1007/s00270-014-0948-4
Pisco J, Bilhim T, Costa NV, Ribeiro MP, Fernandes L, Oliveira AG. Safety and efficacy of prostatic artery chemoembolization for prostate cancer-initial experience. J Vasc Inter Radio. 2018;29:298–305.
doi: 10.1016/j.jvir.2017.10.013
Yassaie O, Silverman JA, Gilling PJ. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: early results. Curr Urol Rep. 2017;18:91.
pubmed: 29046995
doi: 10.1007/s11934-017-0743-2
Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int. 2016;117:923–9.
pubmed: 26477826
doi: 10.1111/bju.13358
Roberts WW. Development and translation of histotripsy: current status and future directions. Curr Opin Urol. 2014;24:104–10.
pubmed: 24231530
pmcid: 3974592
doi: 10.1097/MOU.0000000000000001
McCulloch P, Cook JA, Altman DG, Heneghan C, Diener MK, Group I. IDEAL framework for surgical innovation 1: the idea and development stages. Brit Med J. 2013;346:f3012.
pubmed: 23778427
doi: 10.1136/bmj.f3012
Patelli G, Ranieri A, Paganelli A, Mauri G, Pacella CM. Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Cardiovasc Interventional Radiol. 2017;40:1440–6.
doi: 10.1007/s00270-017-1662-9
Pacella CM, Francica G, Di Lascio FM, Arienti V, Antico E, Caspani B, et al. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J Clin Oncol. 2009;27:2615–21.
pubmed: 19332729
doi: 10.1200/JCO.2008.19.0082
Pacella CM, Mauri G, Achille G, Barbaro D, Bizzarri G, De Feo P, et al. Outcomes and risk factors for complications of laser ablation for thyroid nodules: a multicenter study on 1531 patients. J Clin Endocrinol Metab. 2015;100:3903–10.
pubmed: 26274342
doi: 10.1210/jc.2015-1964
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
pubmed: 1360123
pmcid: 1360123
doi: 10.1097/01.sla.0000133083.54934.ae
Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F. The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. World J Urol. 2011;29:205–10.
pubmed: 20461386
doi: 10.1007/s00345-010-0566-y
Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. WATER: a double-blind, randomized, controlled trial of aquablation((R)) vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol. 2018;199:1252–61.
pubmed: 29360529
doi: 10.1016/j.juro.2017.12.065
Krambeck AE, Handa SE, Lingeman JE. Experience with more than 1,000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol. 2013;189:S141–5.
pubmed: 23234620
doi: 10.1016/j.juro.2012.08.088
Tan AHH, Gilling PJ, Kennett KM, Frampton C, Westemberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation ot the prostatewith transurethral resection of the perostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol. 2003;170:1270–4.
pubmed: 14501739
doi: 10.1097/01.ju.0000086948.55973.00
Kim KS, Choi JB, Bae WJ, Kim SJ, Cho HJ, Hong SH, et al. Comparison of photoselective vaporization versus Holmium laser enucleation for treatment of benign prostate hyperplasia in a small prostate volume. PLoS ONE. 2016;11:e0156133.
pubmed: 27227564
pmcid: 4881985
doi: 10.1371/journal.pone.0156133
Jones P, Rai BP, Somani BK, Aboumarzouk OM. A review of thulium laser vapo-enucleation of the prostate: A novel laser-based strategy for benign prostate enlargement. Arab J Urol. 2015;13:209–11.
pubmed: 26413349
pmcid: 4563004
doi: 10.1016/j.aju.2015.06.007
Roberts WW. New technologies in benign prostatic hyperplasia management. Curr Opin Urol. 2016;26:254–8.
pubmed: 26859557
doi: 10.1097/MOU.0000000000000277
Whelan JP, Bowen JM, Burke N, Woods EA, McIssac GP, Hopkins RB, et al. A prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada. Can Urol Assoc J. 2013;7:335–41.
pubmed: 24319513
pmcid: 3854472
doi: 10.5489/cuaj.180
Yu H, Isaacson AJ, Burke CT. Review of current literature for prostatic artery embolization. Semin Interv Radiol. 2016;33:231–5.
doi: 10.1055/s-0036-1586141
Gao YA, Huang Y, Zhang R, Yang YD, Zhang Q, Hou M, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate–a prospective, randomized, and controlled clinical trial. Radiology. 2014;270:920–8.
pubmed: 24475799
doi: 10.1148/radiol.13122803
Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovascular interventional Radiol. 2016;39:44–52.
doi: 10.1007/s00270-015-1202-4
Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180:246–9.
pubmed: 18499179
doi: 10.1016/j.juro.2008.03.058
Ruszat R, Seitz M, Wyler SF, Abe C, Rieken M, Reich O, et al. GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol. 2008;54:893–901.
pubmed: 18486311
doi: 10.1016/j.eururo.2008.04.053
Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-Year Results. J Urol. 2017;197:1565–72.
pubmed: 28111300
doi: 10.1016/j.juro.2017.01.056
Yafi FA, Tallman CT, Seard ML, Jordan ML Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80–150 cc). Int J Impot Res. 2018;30:209–14.
Rassweiler MC, Mamoulakis C, Kenngott HG, Rassweiler J, de la Rosette J, Laguna MP. Classification and detection of errors in minimally invasive surgery. J Endourol. 2011;25:1713–21.
pubmed: 21877910
doi: 10.1089/end.2011.0068
Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004;172:1926–9.
pubmed: 15540757
doi: 10.1097/01.ju.0000140501.68841.a1
Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010;58:384–97.
pubmed: 20825758
doi: 10.1016/j.eururo.2010.06.005